ASF1A and neoplasm: Another CRISPR screen used an sgRNA library focusing on epigenetic regulators in a syngeneic lung cancer transplant model, identifying Asf1a sgRNAs as being significantly depleted, and validation studies confirmed that Asf1a knockout synergized with anti-PD1 therapy to slow tumor progression by promoting T cell activation [15].